Migraine and Headache

Latest

A Systematic Review of Cluster Headache Among the Pediatric Population

By

Jessica Nye, PhD

The researchers’ goal was to describe the clinical characteristics and therapeutic options available to pediatric patients with cluster headache.

Nurtec ODT Approval Expanded to Include Migraine Prevention

By

Diana Ernst, RPh

Rimegepant is an oral calcitonin gene-related peptide receptor antagonist.

Needle Size Not Tied to Postdural Puncture Headache in Orthopedic Patients

No cases of postdural puncture headache (PDPH) were reported in a cohort of patients receiving spinal injections with smaller or larger needles for spinal anesthesia during orthopedic procedures.

Getting Ahead of Migraines With Current and Emerging Approaches

By

Jessica Nye, PhD

Besides acetaminophen, NSAIDs, triptans, ergot alkaloids, and adjunct antiemetics, gepants and ditans are recently approved for migraine patients.

Atorvastatin With Sodium Valproate Can Reduce Migraine Attacks and Pain Severity

By

Amit Akirov, MD

Atorvastatin may have augmentative effects with sodium valproate in the reduction of migraines with aura.

Combination Treatment Appears Beneficial for Chronic Migraine

By

Cassandra Pardini, PharmD

Data analysis revealed that CGRP mAbs were discontinued more frequently than onabotulinumtoxinA (23% vs 3%).

Projections of Utility of Migraine Disability Assessment Questionnaire

By

Mary Stroka

Researchers believed the MIDAS questionnaire would improve communication and aid in the diagnosis of migraines.

Better Benefit-to-Risk Ratio for Anti-CGRP mAbs Than Current Migraine Preventive Medication

By

Rose Reeb

The researchers compared anti-CGRP mAbs with other drugs for the prevention of episodic and chronic migraine using a likelihood to help versus harm analysis.

Active Occipital Nerve Stimulation May Reduce Aversive Effects of Chronic Migraine

By

Brandon May

This study’s main goal was to investigate how ONS acts on patients’ protective mechanisms and pain-defending protective reflexes.

Atogepant Under Review for Episodic Migraine Prevention

By

Diana Ernst, RPh

Atogepant is an investigational orally administered calcitonin gene-related peptide (CGRP) receptor antagonist.